Literature DB >> 19570102

Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome.

L Wedlake1, R A'Hern, D Russell, K Thomas, J R F Walters, H J N Andreyev.   

Abstract

BACKGROUND: Recurrent, watery diarrhoea affects one-third of patients diagnosed with irritable bowel syndrome ('IBS-D'). Idiopathic bile acid malabsorption ('I-BAM') may be the cause. AIM: To determine the prevalence of I-BAM in patients suffering from IBS-D.
METHODS: A systematic search was performed of publications reporting patients presenting with IBS-D type symptoms, who were subsequently confirmed as having I-BAM by SeHCAT scanning.
RESULTS: Eighteen relevant studies, 15 prospective, comprising 1223 patients were identified. Five studies (429 patients) indicated that 10% (CI: 7-13) patients had severe bile acid malabsorption (SeHCAT 7 day retention <5% of baseline value). 17 studies (1073 patients) indicated that 32% (CI: 29-35) patients had moderate bile acid malabsorption (SeHCAT <10%). 7 studies (618 patients) indicated that 26% (CI: 23-30) patients had mild (SeHCAT <15%) bile acid malabsorption. Pooled data from 15 studies showed a dose-response relationship according to severity of malabsorption to treatment with a bile acid binder: response to colestyramine occurred in 96% of patients with <5% retention, 80% at <10% retention and 70% at <15% retention.
CONCLUSIONS: Idiopathic adult-onset bile acid malabsorption is not rare. International guidelines for the management of irritable bowel syndrome need to be revised so that clinicians become more aware of this possibility.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19570102     DOI: 10.1111/j.1365-2036.2009.04081.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  115 in total

Review 1.  Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome.

Authors:  Michael Camilleri; David A Katzka
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-08       Impact factor: 4.052

2.  Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea.

Authors:  Banny S Wong; Michael Camilleri; Paula Carlson; Sanna McKinzie; Irene Busciglio; Olga Bondar; Roy B Dyer; Jesse Lamsam; Alan R Zinsmeister
Journal:  Clin Gastroenterol Hepatol       Date:  2012-05-18       Impact factor: 11.382

3.  Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea.

Authors:  Banny S Wong; Michael Camilleri; Paula J Carlson; Suwebatu Odunsi-Shiyanbade; Sanna McKinzie; Irene Busciglio; Duane Burton; Alan R Zinsmeister
Journal:  Dig Dis Sci       Date:  2012-01-21       Impact factor: 3.199

4.  Are the definitions for chronic diarrhoea adequate? Evaluation of two different definitions in patients with chronic diarrhoea.

Authors:  Per-Ove Stotzer; Hasse Abrahamsson; Antal Bajor; Anders Kilander; Riadh Sadik; Henrik Sjövall; Magnus Simrén
Journal:  United European Gastroenterol J       Date:  2015-08       Impact factor: 4.623

5.  Managing bile acid diarrhoea.

Authors:  Julian R F Walters; Sanjeev S Pattni
Journal:  Therap Adv Gastroenterol       Date:  2010-11       Impact factor: 4.409

6.  Irritable bowel syndrome-diarrhea: characterization of genotype by exome sequencing, and phenotypes of bile acid synthesis and colonic transit.

Authors:  Michael Camilleri; Eric W Klee; Andrea Shin; Paula Carlson; Ying Li; Madhusudan Grover; Alan R Zinsmeister
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-07       Impact factor: 4.052

7.  Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function.

Authors:  Suwebatu T Odunsi-Shiyanbade; Michael Camilleri; Sanna McKinzie; Duane Burton; Paula Carlson; Irene A Busciglio; Jesse Lamsam; Ravinder Singh; Alan R Zinsmeister
Journal:  Clin Gastroenterol Hepatol       Date:  2009-10-30       Impact factor: 11.382

Review 8.  Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology.

Authors:  Nicholas J Talley; Gerald Holtmann; Marjorie M Walker
Journal:  J Gastroenterol       Date:  2015-04-29       Impact factor: 7.527

9.  Analysis of Fecal Primary Bile Acids Detects Increased Stool Weight and Colonic Transit in Patients With Chronic Functional Diarrhea.

Authors:  Priya Vijayvargiya; Michael Camilleri; Victor Chedid; Paula Carlson; Irene Busciglio; Duane Burton; Leslie J Donato
Journal:  Clin Gastroenterol Hepatol       Date:  2018-06-12       Impact factor: 11.382

10.  New and Emerging Treatment Options for Irritable Bowel Syndrome.

Authors:  Brian E Lacy; William D Chey; Anthony J Lembo
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.